Oncogenic GOPC-ROS1 Fusion Identified in a Congenital Glioblastoma Case

Susan L. Whiteway*, Aaron M. Betts, Erika R. O'Neil, Adam L. Green, Ahmed Gilani, Brent A. Orr, Derek A. Mathis

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

6 Scopus citations

Abstract

Congenital glioblastoma (GBM) is a rare brain tumor of infancy. While histologically they resemble pediatric and adult GBM, growing evidence suggests a distinct molecular profile. We report the case of a 7-day-old infant female with congenital GBM found to harbor a GOPC-ROS1 fusion. She underwent surgical resection, moderate-intensity chemotherapy without radiation, and remains disease-free 4 years from completion of therapy. While the frequency of this mutation is not known, the identification of this oncogenic driver may provide insight into the pathogenesis of GBM in this age group and may serve as a molecular target for select patients.

Original languageEnglish
Pages (from-to)e813-e818
JournalJournal of Pediatric Hematology/Oncology
Volume42
Issue number8
DOIs
StatePublished - 1 Nov 2020

Keywords

  • chemotherapy
  • congenital glioblastoma
  • GOPC-ROS1 fusion

Cite this